Project Narrative This research will test the potential to repurpose a small molecule BRAF kinase inhibitor, dabrafenib, an FDA- approved drug for several cancers, for new use in preventing cisplatin- induced hearing loss. Significant protection against cisplatin-induced hearing loss has been achieved with oral delivery of dabrafenib in mouse models in doses approved in humans. The successful completion of this study will provide the crucial data needed for rapidly advancing dabrafenib to clinical studies in humans for prevention of hearing loss.
|Effective start/end date||1/1/21 → 12/31/22|
- National Institute on Deafness and Other Communication Disorders: $373,034.00
- National Institute on Deafness and Other Communication Disorders: $402,857.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.